News
-
-
PRESS RELEASE
AMOEBA prepares for the commercial launch of the AXPERA Product Line in the USA with approval expected by 2025
Amoéba's biofungicide products receive US EPA's admissibility confirmation for registration dossier, accelerating industrial and commercial development. Application for market authorization has been submitted. Collaboration with Dunham Trimmer in progress -
-
REGULATED PRESS RELEASE
AMOEBA: A NEW LEGAL STRUCTURE TO MAXIMISE COMMERCIAL ACTIVITIES
Amoéba announces a reorganisation to enhance commercial activities in biocontrol and cosmetics sectors, aiming to create value for shareholders. New legal structure to optimize resources and facilitate partnerships -
-
-
-
-
-
REGULATED PRESS RELEASE
AMOEBA: ORDINARY AND EXTRAORDINARY GENERAL MEETING OF 27 JUNE 2024 - Availability of preliminary documents
Amoéba announces Ordinary and Extraordinary General Meeting on June 27, 2024, in Chassieu. Shareholders can access preliminary documents online. Electronic voting available